Biogen has discontinued all gene therapy programs using adeno-associated virus (AAV) capsids, instead shifting resources to modalities that have the highest likelihood of achieving better treatment ...
The CHOP's research team findings support the hypothesis that rare AAV integration can contribute to human oncogenesis, which ...
After a patient died following a high dose of Neurogene’s Rett syndrome gene therapy candidate, the biotech is sharing details about the event and the new safety protocols being incorporated into the ...
While the overwhelming scope of tragic outcomes from HIV infection at the origin of the AIDS epidemic are in the past, those living with HIV still require daily treatments. One option includes ...
Morning Overview on MSN
A gene therapy injected straight into brain tumors just began dosing its first patients — a virus engineered to kill glioblastoma cells and spare the rest
Somewhere in an operating room this spring, a neurosurgeon did something that has never been done before: while removing a ...
The development of efficient and safe delivery systems is a cornerstone of gene therapy and genome editing. Lipid nanoparticles (LNPs), adeno-associated ...
Viral vectors dominate gene therapy, with lentivirus, adenovirus, and AAV being key players, each with unique advantages and limitations. Non-viral vectors, such as lipid nanoparticles and GalNAc, ...
Research Describes the Potential of JCR’s Platform Technologies, Including JUST-AAV Gene Therapy, to Facilitate Delivery of Therapies to the Central Nervous System -HYOGO, Japan--(BUSINESS WIRE)--JCR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results